国际英语资讯:Spotlight: U.S.-China biotech cooperation benefits patients, investors in both countries_时事

国际英语资讯:Spotlight: U.S.-China biotech cooperation benefits patients, investors in both countries

Chinese medical establishments and investors are eagerly searching for quality biotech programs in the United States. The Chinese medical institutes will cooperate with U.S. biotech companies to license in their technologies, initiate clinical trials upon the approval of SFDA, and ultimately sell the legal drugs. Such cooperation has been normal in the Chinese market, Guo said.

"About 30 percent investors of INmune Bio are from the Chinese mainland," Guo said, adding that "Univest Securities has a dream to bring quality U.S. technologies to China and benefit the Chinese people."

Share price of INmune Bio surged 1.84 dollars, or 21.40 percent, on Tuesday to close at 10.44 U.S. dollars per share.

"I think the fact that the share price is beginning to move is a reflection that people have begun to understand all our programs, understand what we're trying to do, and hopefully reflects the fact that they think we have great prospects," Tesi said with excitement.

"If you make patients better, investors do well. And those are two customers, investors and patients... They're equally important," he added.

INmune Bio went public in Nasdaq Stock Market on Feb. 4 with public offering price at 8 dollars per share. The company aimed to raise up to 20 million dollars to fund its research and drug development activities.

It is a clinical-stage biotechnology company that focuses on reprogramming the innate immune system to fight diseases, such as cancer, neurodegenerative disease, malignancy and Alzheimer's disease.